Registration No. 333-289874 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on December 17, 2025. AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) Delaware 2080 46-4069365 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 4030 Black Gold Drive, Dallas, Texas 75247 (214) 308 5003 (Address, inc ...

Core Insights - Medline Inc. shares are expected to open 16% higher than their IPO price, raising $6.26 billion in the largest IPO of the year [1][2] - The IPO pricing values Medline at approximately $39 billion, making it a significant player in the medical supply industry [2][5] - The successful IPO concludes the US IPO calendar for the year, setting a positive tone for future listings, including a potential SpaceX debut in 2026 [3] Company Overview - Medline manufactures and distributes essential medical supplies such as gloves, gowns, and exam tables for hospitals and doctors [1] - The company was acquired in a $34 billion leveraged buyout by Blackstone Inc., Carlyle Group Inc., and Hellman & Friedman in 2021 [1] Market Context - The IPO surpassed the previous largest listing of the year, which was a $5.26 billion offering by Contemporary Amperex Technology Co. Ltd. [2] - Medline's IPO is the largest in the US since Rivian Automotive Inc.'s $13.7 billion deal in 2021 [2] - The total amount raised from first-time share sales in the US this year exceeds $46 billion, indicating a strong market despite previous disruptions [4] Investment Details - Medline secured up to $2.35 billion in commitments from cornerstone investors, including notable firms like Baillie Gifford and Morgan Stanley [6] - The upsized offering included proceeds from over 37 million shares designated for purchasing stock from pre-IPO shareholders, allowing private equity firms to realize returns without selling shares outright [7]

CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters†or "the Company†), the innovative aerospace company, owner and operator of the world's largest commercial supersonic aircraft fleet, out of NASA's Kennedy Space Center, today announced the completion of its Initial Public Offering ("IPO†), raising $40 million through the sale of 11,142,061 shares of common stock (the "Common Stock†) at a public offering price of $3.59 per share. This final closing resulted in the issuance o ...

A day that featured the biggest initial public offering in four years also saw the Nasdaq Composite close sharply lower.The tech-heavy index slid 1.8%. The S&P 500 dropped 1.1%. The Dow Jones Industrial Average fell 230 points, or 0.5%. The S&P and Dow extended their respective losing streaks to four days.Struggles for the Nasdaq were in stark contrast to Medline, which surged in its debut on the tech-heavy index under the MDLN ticker. It raised $6.26 billion in the initial public offering, which makes it t ...

分组1 - The article discusses the resurgence of IPOs, particularly in the private equity space, with a focus on the successful Medline deal, which is noted as the largest healthcare leveraged buyout ever [1][2] - Private equity firms are expected to increase their activity in Q1, although there is skepticism based on past predictions that did not materialize [3] - The article highlights the challenges faced by companies like Wealthfront, which did not meet the new IPO revenue threshold of $500 million, indicating a potential shift towards smaller deals in the market [4][5][6] 分组2 - The Medline deal was complex due to pandemic-related revenue uncertainties, but it has since expanded internationally, setting a precedent for future private equity transactions [2] - Wealthfront, despite being an older company, struggled with growth metrics necessary for a successful public offering, reflecting broader market challenges for similar firms [5][6] - The article suggests that there is a growing interest in AI-related investments, as investors seek opportunities beyond traditional sectors [5]

Core Insights - The discussion focused on the current and upcoming IPO market outlook for 2026, highlighting the impact of the government shutdown on previously planned IPOs and their delays [1] Group 1: Steve Parish's Role and Experience - Steve Parish serves as Managing Partner, Equity Capital Markets at ICR Capital, advising corporate management teams and financial sponsors on public equity market monetizations, including IPOs and follow-on offerings [2] - With a career spanning over a decade as an Equity Capital Markets Advisor, Steve has advised U.S. and international issuers on multiple equity transactions [3] - He has a significant background at Bear Stearns & Co, where he held senior leadership roles in equity capital markets and oversaw over 1000 public equity and equity-linked offerings [3] Group 2: About ICR - ICR was founded in 1998 by three former Wall Street analysts, focusing on strategic communications and advisory solutions for companies at various growth stages [5] - The firm has gained global recognition for its expertise in public relations, investor relations, and capital markets advisory solutions [6]

Core Insights - Medline shares experienced a significant increase of nearly 25% during their trading debut, with the stock priced around $36 after an IPO that raised $6.26 billion, marking one of the largest IPOs in recent years [1][4][7] Company Overview - Medline sold over 216 million shares at $29 each, at the higher end of its anticipated range of $26 to $30, with plans to use the proceeds to reduce debt [2][4] - The company offers over 335,000 medical and surgical products, including protective equipment and testing kits, and has reported consistent annual sales growth since its inception [2] Financial Performance - For the first nine months of the year ending September, Medline reported a net income of $977 million on revenues of $20.65 billion, an increase from a net income of $911 million on $18.72 billion in revenue during the same period the previous year [3] Market Context - The IPO marks a recovery in the IPO market, although overall activity remains below the record levels seen in 2021; Medline's IPO is the largest since Rivian's $11.93 billion IPO in 2021 [4][7] Strategic Vision - CEO Jim Boyle expressed that the IPO is expected to enhance Medline's brand, positioning the company as the "Costco of healthcare" for its medical equipment customers, leveraging its private label products and strong supply chain [5]

Group 1 - Medline shares commenced trading under the ticker 'MDLN' on Wednesday, marking the largest IPO since 2021 [1]

Core Insights - Medline is debuting on the Nasdaq after raising $6.26 billion in one of the largest IPOs in recent years, selling over 216 million shares at $29 each, at the higher end of its anticipated range [1][6] - The company plans to use the IPO proceeds to reduce its debt [1] Company Performance - Medline sells over 335,000 medical and surgical products and has reported consistent annual sales growth since its founding [2] - For the first nine months of the year ending in September, Medline reported a net income of $977 million on revenues of $20.65 billion, an increase from $911 million in net income on $18.72 billion in revenue during the same period the previous year [2] Market Context - Medline's IPO is part of a recovering IPO market, although overall activity remains below the record levels of 2021; the $6.26 billion raised is the largest since Rivian's IPO in 2021 [3] - CEO Jim Boyle stated that the IPO is expected to enhance Medline's brand, positioning the company as the "Costco of healthcare" for its customers [4]

Core Viewpoint - Medline, a U.S. medical supplies giant, is set to debut on the Nasdaq with the largest initial public offering (IPO) of the year, raising $6.26 billion at a share price of $29, which gives the company a market value of at least $37 billion [1][2]. Group 1: IPO Details - Medline's IPO is the largest U.S. listing since Rivian's $13.7 billion deal in November 2021, with over 200 IPOs priced this year despite market volatility [2]. - The company will trade under the symbol "MDLN" on the Nasdaq [1]. Group 2: Company Background - Medline is described as "the largest company you've never heard of," emphasizing its extensive presence in the market despite limited advertising and marketing efforts [2]. - The company was acquired by three private equity firms—Blackstone, Carlyle, and Hellman & Friedman—in 2021 for $34 billion, marking the largest leveraged buyout since the financial crisis [3].